Citi downgraded CME Group (CME) to Neutral from Buy with a price target of $250, down from $255. CME has benefited from “numerous positive catalysts,” including the dividend and buyback plan announcement, 2025 price increases, fading concerns on competitive front, and solid volumes, the analyst tells investors in a research note. However, after two solid years of double-digit sales growth, Citi expects to see “more muted growth” this year and is currently forecasting 4% sales growth in 2025. The firm expects the stock to hold given its defensive qualities but prefers to wait for a better entry point and/or clearer fundamental catalysts to put new money to work in it from here.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group Updates Clearing House Fee Schedule
- CME Group price target raised to $257 from $231 at Barclays
- Mali Issues Arrest Warrant for Barrick Gold (GOLD) CEO amid Rising Tensions
- CME Group Announces Share Repurchase and Dividend Plan
- CME Group announces $2.1B annual variable dividend, $3B share repurchase plan